
XAIR Stock Forecast & Price Target
XAIR Analyst Ratings
Bulls say
Beyond Air is in a positive position due to its successful development of a Nitric Oxide Generator and Delivery System for the potential treatment of respiratory diseases. The termination of a previous transaction may have caused uncertainty, but management has reassured its commitment to exploring strategic alternatives and maintaining operational focus on its core delivery franchise. The company’s strong financials, with projected revenues of $386.6 million in 2022, further support its potential for growth and success in the market.
Bears say
Beyond Air is in a transition phase as it shifts its focus to commercializing its LungFit PH product and scaling its operations under the leadership of newly appointed CEO Robert Goodman. The company has shown promising revenue growth and a strong international distribution footprint, but it is still early stages and the success of its product will depend on go-to-market execution and converting its current customer base into consistent revenue streams. Furthermore, Beyond Air's UNO product, while showing potential as a locally delivered immunotherapeutic approach, still has limitations in terms of a small sample size and lack of randomized controls. However, the management's strategic positioning of UNO as an immunotherapy enhancer may attract potential investment opportunities in the future. Overall, the current financial and operational data do not indicate strong potential for immediate success, and investors should closely monitor Beyond Air's ability to execute its commercial strategy and generate consistent revenue.
This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.
XAIR Analyst Forecast & Price Prediction
Start investing in XAIR
Order type
Buy in
Order amount
Est. shares
0 shares